This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	E1A binding protein p300 (EP300; p300); AML1-ETO oncogenic fusion protein	Cell culture and mouse studies suggest inhibiting p300 could help treat AML1-ETO-positive AML. AML1-ETO fusion is the cause of 10%–15% of AML cases. In AML1-ETO fusion-positive cells isolated from patients, a p300 inhibitor lowered growth compared with control compound. In mice, injection of leukemia cells pretreated with a p300 inhibitor led to greater survival than injection of leukemia cells receiving control compound. Next steps include inhibiting p300 in additional mouse models of leukemia.	Patent application filed; available for licensing	Wang, L. <i>et al. Science</i> ; published online July 14, 2011; doi:10.1126/science.1201662 Contact: Stephen D. Nimer, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: nimers@mskcc.org
<i>SciBX</i> 4(30); doi:10.1038/scibx.2011.847 Published online Aug. 4, 2011				